The discovery and development of Eg5 inhibitors for the clinic

James A. D. Good, Giacomo Berretta, Nahoum G. Anthony, Simon P. Mackay

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)


The mitotic kinesin Eg5 (also known as kinesin spindle protein, KSP, Kif11, a member of the kinesin-5 family) represents an attractive oncology drug target in the ongoing development of anti-mitotic drugs that selectively block mitosis through disruption to the mitotic spindle. In this state-of-the-art review, we outline the progress that has been made in the development of Eg5 inhibitors for clinical use. We evaluate the preclinical development and attributes of key Eg5 inhibitors that have undergone clinical evaluation or extensive preclinical optimisation, and discuss the medicinal chemistry strategies utilised in their design to overcome the challenges encountered during lead optimisation. We critically analyse the progress that has been made towards delivering clinical benefits, and the wider implications this has in the utility of mitotic kinesin inhibitors as prospective oncology drugs.

Original languageEnglish
Title of host publicationKinesins and Cancer
EditorsFrank Kozielski
PublisherSense Publishers
Number of pages26
ISBN (Print)978-94-017-9731-3
Publication statusPublished - 1 Jan 2015


  • anti-mitotic
  • drug discovery
  • Eg5
  • kinesins
  • multiple myeloma


Dive into the research topics of 'The discovery and development of Eg5 inhibitors for the clinic'. Together they form a unique fingerprint.

Cite this